Thursday, September 23, 2010 10:23:59 PM
LOL!!!!!!
My cousin's husband is fighting that rare cancer, has been for a couple of years. But it is extremely rare, thus of negligable market value I think, unless they plan to expand it use like CYTR is doing with another drug? I see from your post, that they ,landed some cash. Shame they are not more open with US investors about what they are doing. I held the stock for ages, but finally gave up 6-9 months ago.
My cousin's husband is fighting that rare cancer, has been for a couple of years. But it is extremely rare, thus of negligable market value I think, unless they plan to expand it use like CYTR is doing with another drug? I see from your post, that they ,landed some cash. Shame they are not more open with US investors about what they are doing. I held the stock for ages, but finally gave up 6-9 months ago.
Recent XTLB News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/22/2026 08:11:21 PM
- XTL Announces Receipt of Staff Delist Determination from Nasdaq • GlobeNewswire Inc. • 05/22/2026 08:10:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/15/2026 09:09:16 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/07/2026 12:10:18 PM
- Form NT 20-F - Notification of inability to timely file Form 20-F • Edgar (US Regulatory) • 04/30/2026 08:34:40 PM
- Washington Just Opened the Door to Psychedelic Medicine; This Microcap Already Has a Key • AllPennyStocks.com • 04/29/2026 08:21:50 PM
- XTL Biopharmaceuticals (XTLB) acquisition of Psyga Bio targets psychedelic biotech growth • IH Market News • 04/29/2026 02:47:52 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/29/2026 01:07:41 PM
- XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies • GlobeNewswire Inc. • 04/29/2026 12:58:51 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/23/2026 08:01:14 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/20/2026 08:11:31 PM
- XTL Biopharmaceuticals Announces ADS Ratio Change • GlobeNewswire Inc. • 03/20/2026 08:10:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/10/2026 08:05:03 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/27/2026 09:34:26 PM
- XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing • GlobeNewswire Inc. • 02/27/2026 09:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/24/2026 09:05:06 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/23/2026 09:05:27 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/17/2026 09:05:16 PM
- XTL Update on Recent Developments • GlobeNewswire Inc. • 01/29/2026 09:05:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/28/2026 01:58:46 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/23/2026 09:15:09 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/23/2026 09:15:09 PM
- XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders’ Equity Deficiency • GlobeNewswire Inc. • 01/23/2026 09:10:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/13/2026 09:05:32 PM
